NLTX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 des 2023 @ 22:00):

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology...

Stats
Dagens volum	109 095
Gjennomsnittsvolum	5 520.00
Markedsverdi	8.20M
EPS	$0 ( 2024-03-19 )
Neste inntjeningsdato	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.284
ATR14	$0.878 (25.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-16	Woods Robert Keith	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Palekar Rohan	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Noonberg Sarah B.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Freedland Cory S.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Baffi Robert	Buy	15 400	Stock Option (Right to Buy)

INSIDER POWER
75.00
Last 94 transactions
Buy: 7 989 742 \| Sell: 1 025 638

Volum Korrelasjon

Lang: -0.32 (neutral)

Kort: -0.52 (weak negative)

Signal:(16.09) Neutral

Neoleukin Therapeutics Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Neoleukin Therapeutics Korrelasjon - Valuta/Råvare

-0.04
( neutral )

0.06
( neutral )

-0.14
( neutral )

0.10
( neutral )

-0.16
( neutral )

-0.18
( neutral )

Neoleukin Therapeutics Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-1.010

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-1.010

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.100

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.